Amplified inhibition of atherosclerotic plaque-induced platelet activation by glenzocimab with dual antiplatelet therapy.

Date publication

août 2023

Journal

Journal of thrombosis and haemostasis : JTH

Auteurs

Membres identifiés du Cancéropôle Est :
Dr MANGIN Pierre

Tous les auteurs :
Alenazy FO, Harbi MH, Kavanagh DP, Price J, Brady P, Hargreaves O, Harrison P, Slater A, Tiwari A, Nicolson PLR, Connolly DL, Kirchhof P, Kalia N, Jandrot-Perrus M, Mangin PH, Watson SP, Thomas MR

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/37541591

Résumé

Aspirin and platelet P2Y inhibitors, such as ticagrelor, suboptimally inhibit microvascular thrombosis during ST-elevation myocardial infarction (STEMI). GPIIb/IIIa inhibitors may further inhibit this, but cause excessive bleeding. We investigated whether combination of glenzocimab, a GPVI inhibitor, with aspirin and ticagrelor provides additional antithrombotic effects, as GPVI has a critical role in atherothrombosis but minimal involvement in haemostasis.

Mots clés

Acute coronary syndromes, GPVI, antiplatelet therapy, atherosclerotic plaque, platelets

Référence

J Thromb Haemost. 2023 08 2;: